• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, July 9

Wockhardt Ltd has received approval from the US Food and Drug Administration to market Fosphenytoin injections containing 50 mg Phenytoin equivalents/ml.

This injectible is used to treat complicated forms of epileptic seizures, where oral medicines cannot be administered, the company told the BSE.

Wockhardt USA Inc, the US subsidiary of the company, will launch Fosphenytoin in the US on August 6, 2007, a day after the patent expires on August 5, the company said.

Fosphenytoin is the generic name for the brand Cerebyx, sold in the US by Eisai Inc and Pfizer. As per IMS, the US market for Fosphenytoin injection is about $73 million.

Wockhardt’s Chairman, Mr Habil Khorakiwala, said in the statement that Fosphenytoin will be its third product to be launched on Day-1 after patent expiry. “It is a very significant addition to our sterile portfolio for the US market.”

Wockhardt USA Inc at present markets 22 products in the US.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Conergy installs hybrid power systems in ONGC platforms

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line